Table 3.
Characteristics of patients with and without acute biliary events
| ABE group (n = 195) | Non-ABE group (n = 159,371) | |
|---|---|---|
| Age (years)a* | 66.2 ± 13.5 | 56.6 ± 19.7 |
| Maleb | 132 (67.7) | 109,399 (68.6) |
| Tuberculosis diagnostic yearb | ||
| 1996–2000 | 60 (30.8) | 48,844 (30.6) |
| 2001–2005 | 73 (37.4) | 59,424 (37.3) |
| 2006–2010 | 62 (31.8) | 51,103 (32.1) |
| Co-morbidity (%) | ||
| Diabetes mellitusb* | 63 (37.4) | 38,075 (23.9) |
| Chronic obstructive pulmonary diseaseb | 10 (5.1) | 7918 (5.0) |
| Malignancyb | 12 (6.2) | 6712 (4.2) |
| End-stage renal diseasec | 2 (1.0) | 1998 (1.3) |
| Connective tissue diseasec | 0 (0.0) | 1151 (0.7) |
| Acquired immunodeficiency syndromec | 1 (0.5) | 562 (0.4) |
| Liver cirrhosisc | 1 (0.5) | 323 (0.2) |
| Transplantationc* | 1 (0.5) | 137 (0.1) |
| Pneumoconiosisc | 0 (0) | 85 (0.1) |
| Low incomeb | 5 (2.6) | 4830 (3.0) |
| Total duration of anti-TB treatment | 266.9 ± 99.7 | 260.4 ± 105.8 |
| Intensive phase (initial 60 days)a | ||
| No. of days covered by isoniazida | 47.7 ± 18.6 | 50.0 ± 11.2 |
| No. of days covered by rifamycina* | 48.9 ± 13.4 | 51.7 ± 11.2 |
| No. of days covered by ethambutola | 51.2 ± 11.4 | 50.8 ± 13.1 |
| No. of days covered by pyrazinamidea | 39.9 ± 21.3 | 42.5 ± 20.4 |
| Initial 180 days | ||
| No. of days covered by isoniazida* | 134.4 ± 52.2 | 142.4 ± 53.4 |
| No. of days covered by rifamycina* | 140.1 ± 37.9 | 152.5 ± 32.8 |
| No. of days covered by ethambutola | 145.2 ± 35.6 | 141.9 ± 42.2 |
| No. of days covered by pyrazinamidea | 67.8 ± 44.9 | 69.3 ± 45.8 |
Data are presented as number (%) or mean ± standard deviation
aCompared using an independent-sample t test
bCompared using a chi-square test
cCompared using a Fisher exact test
*p < 0.05 for the comparison between the ABE and non-ABE groups